Novo Nordisk and Echosens partner up to develop diagnostics for "silent disease"

NASH, a metabolic liver disease, has no early stage symptoms, and people therefore go undiagnosed, which the two firms are now seeking to change.

Photo: Marcus Trappaud Bjørn/ERH

NASH, or non-alcoholic steatohepatitis, is a focus area of Danish pharmaceutical giant Novo Nordisk – however, the disease’s nature poses a particular problem when it comes to treatment as it often goes undiagnosed until it is too late.

On Wednesday, Novo Nordisk announced a new partnership with Echosens endeavoring to diagnose the ”silent disease” earlier as well as spread awareness among patients and healthcare professionals.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs